Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had previously received two doses of ChAdOx1 or he...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanchaijiraboon, Passakorn, Sainamthip, Panot, Teeyapun, Nattaya, Luangdilok, Sutima, Poovorawan, Yong, Wanlapakorn, Nasamon, Tanasanvimon, Suebpong, Sriuranpong, Virote, Susiriwatananont, Thiti, Zungsontiporn, Nicha, Pakvisal, Nussara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965854/
https://www.ncbi.nlm.nih.gov/pubmed/36851234
http://dx.doi.org/10.3390/vaccines11020356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965854/
https://www.ncbi.nlm.nih.gov/pubmed/36851234
http://dx.doi.org/10.3390/vaccines11020356

Ejemplares similares